Osmetech has launched a genetic test for CYP450 2C9 drug metabolism. The test identifies polymorphisms in the CYP2C9 gene, which the company said is associated with the metabolism of 10 percent of all drugs, including non-steroidal anti-inflammatory drugs, anticoagulants, anti-epileptic agents, cholesterol-lowering drugs, and anti-diabetic agents.
The CYP2C9 test is available for research use only on the company’s eSensor XT-8 System. The company said it “may also seek FDA approval” for the test.